KROS
Keros Therapeutics Inc
11.40$
+0.9%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +1,687.5% | -42.0% | -55.4% | +948.6% | +684.0% | +6,844.3% | -91.4% | -21.5% | -97.3% | -4.7% | +4,850.4% | – | |
| – | -55.2% | +12.1% | +10.5% | +2.6% | +5.7% | +3.6% | +7.6% | +6.8% | +1.3% | +0.8% | – | – | |
| – | – | -42.0% | -55.4% | +100.0% | +3,562.2% | +7,695.1% | -91.6% | -22.1% | -97.2% | -109.4% | – | – | |
| – | +9.8% | +2.0% | +5.9% | +21.5% | -7.3% | +6.7% | -10.7% | -55.1% | -8.2% | -10.1% | +38.7% | – | |
| – | -0.5% | +13.2% | -3.4% | -1.4% | +8.6% | -1.6% | +38.0% | -30.1% | +16.0% | -13.6% | -15.2% | – | |
| – | +9.0% | +4.2% | +3.9% | +16.4% | -4.7% | +5.8% | -2.7% | -49.2% | +1.4% | -12.9% | +19.7% | – | |
| – | – | – | – | – | – | – | -126.2% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | -120.8% | – | – | – | – | – | |
| – | – | -107.3% | – | – | – | +3,247.7% | -122.1% | – | – | – | – | – | |
| – | – | – | – | – | – | – | -120.7% | – | – | – | – | – | |
| – | – | – | – | – | – | – | -120.5% | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.